Limiting Systemic Plasminogenolysis Reduces the Bleeding Potential for Tissue-type Plasminogen Activators but not for Streptokinase

Summary

Clinical experience suggests that thrombolytic-induced bleeding is associated with systemic activation of the thrombolytic system. Using fibrin specific variants of tissue-type plasminogen activator (t-PA) and making use of the apparent fibrin specificity of streptokinase (SK) in the rabbit we tested the hypothesis that minimizing systemic plasmin production and fibrinogenolysis will decrease hemorrhages in models of peripheral bleeding and embolic stroke. t-PA consumed 51% of the available fibrinogen; caused cerebral bleeds and increased peripheral bleeding time. Fibrin-specific variants of t-PA depleted less than 20% of the fibrinogen and did not cause peripheral or cerebral bleeding. However, an equipotent dose of SK converted only 12% of the available fibrinogen but increased bleeding time and caused hemorrhagic conversion in 75% of embolic stroke model animals treated. The data suggest that bleeding associated with tissue-type plasminogen activators is linked to systemic plasmin generation and subsequent fibrinogenolysis. This hypothesis does not explain the mechanism(s) of SK-in-duced bleeding.

• References

• 1 Hoylaerts M, Dingeman CR, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982; 257: 2912-2919
• 2 Reddy KNN, Markus G. Mechanism of activation of human plasminogen by streptokinase. J Biol Chem 1972; 247: 1683-1691
• 3 Lublin IM, Hayzer DJ, Runge MS. Strategies for the design of novel thrombolytic and antithrombolytic agents. Trends Cardiovasc Med 1992; 2: 84-89
• 4 Califf RM, Stump D, Thorton D, Kereiakes DJ, George BS, Abbotsmith CW, Candella RJ, Boswick JM, Topol EJ. The TAMI Study Group: Hemorrhagic complications after tissue plasminogen (t-PA) therapy for acute myocardial infarction (abstract). Circulation 1987; 76: 1
• 5 Alfred ER, Arnold MD, Bower RW, Collen D, Lubsen J, Serruys PW, Simoons ML, Verstraete M. Systemic fibrinogenolysis after recombinant human tissue-type plasminogen activator for myocardial infarction: influence in coronary patency and bleeding (abstract). J Am Coll Cardiol 1988; 11: 107A
• 6 Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterund G, Robertson TL, Terrin ML. Thrombolysis in myocardial infarction (TIMI) trial-Phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patient treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11: 1-11
• 7 Stump DC, Califf RM, Topol EJ, Sigmon K, Thornton D, Masek R, Anderson L, Collen D. The TAMI Group. Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. Circulation 1989; 80: 1222-1230
• 8 Bovill EG, Terrin ML, Stump DC, Berke AD, Friderick M, Collen D, Feit F, Gore JM, Hillis LD, Lambrew CT, Leiboff R, Mann KG, Markis JE, Pratt CM, Sharkey SW, Sopko G, Tracy RP. Chesebro JH for the TIMI Investigators. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, Heparin, and aspirin for acute myocardial infarction. Annal Int Med 1991; 115: 256-265
• 9 Bennett WF, Paoni NF, Keyt BA, Botstein D, Jones AJS, Presta L, Wurm FM, Zoller MJ. High resolution analysis of functional determinants on human tissue-type plasminogen activator. J Biol Chem 1991; 266: 5191-5201
• 10 Paoni NP, Refino CJ, Brady K, Pena LC, Nguyen HV, Kerr EM, Johnson AC, Wurm FM, van Reis R, Botstein D, Bennett WF. Involvement of residues 269-299 in the enzymatic activity of tissue-type plasminogen activator. Prot Eng 1992; 5: 259-266
• 11 Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, Lai J, Pena L, Pater C, Ogez J, Etcheverry T, Botstein D, Bennett WF. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994; 91: 3670-3674
• 12 Paoni NF, Keyt BA, Refino CJ, Chow AM, Nguyen HV, Berleau LT, Badillo J, Pena LC, Brady K, Wurm FM, Ogez J, Bennett WF. A slow clearing, fibrin-specific, PAI-1 resistant variant of t-PA (T103N, KHRR 296-299 AAAA). Thromb Haemost 1993; 70: 307-312
• 13 Hotchkiss A, Refino CJ, Leonard CK, O’Connor JV, Crowley C, McCabe J, Tate K, Nakamura G, Powers D, Levinson A, Mohler M, Spellman MW. The influence of carbohydrate structure on the clearance of recombinant tissue-type plasminogen activator. Thromb Haemost 1988; 60: 255-261
• 14 Cole SE, Nichols EH, Poisson L, Harnois ML, Livingston DJ. In vivo clearance of tissue plasminogen activator: The complex role of sites of glycosy-lation and level of sialylation. Fibrinolysis 1993; 7: 15-22
• 15 Thomas GR, Thibodeaux H, Errett CJ, Badillo JM, Keyt BA, Refino CJ, Zivin JA, Bennett WF. A long-half-life and fibrin specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding. Stroke 1994; 25: 2072-2079
• 16 Summaria L, Arzadon L, Bernabe P, Robbins KC. The interaction of streptokinase with human, cat, dog and rabbit plasminogens. The fragmentation of streptokinase in the equimolar plasminogen-streptokinase complexes. J Biol Chem 1974; 249: 4760-4769
• 17 Lijnen HR, Stassen JM, Vanlinthout I, Fukao H, Okada K, Matsuo O, Collen D. Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis. Thromb Haemost 1991; 66: 468-473
• 18 Verstraete M, Vermylen J, Amery A, Vermylen C. Thrombolytic therapy with streptokinase using a standard dosage scheme. Brit Med J 1966; 1: 454-456
• 19 Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human Adenovirus 5 DNA. Virology 1973; 52: 456-457
• 20 Thomas GR, Thibodeaux H, Bennett WF, Refino CJ, Badillo JM, Errett CJ, Zivin JA. Optimized thrombolysis of cerebral clots with tissue-type plasminogen activator in a rabbit model of embolic stroke. J Pharmacol Exp Ther 1992; 264: 67-73
• 21 Zar JH. Biostatistical Analysis. Prentice Hall, Englewood Cliffs, NJ 1984
• 22 Gardell SJ, Ramjit DR, Stabilito II, Fujita T, Lynch JJ, Cuca GC, Jain D, Wang S, Tung J-S, Mark GE, Shebuski RJ. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits. Circulation 1991; 84: 244-253
• 23 Gardell SJ, Hare TR, Bergum PW, Cuca GC, O’Neill-Palladino L, Zavod-ny SM. Vampire bat salivary plasminogen activator is quiescent in human plasma in the absence of fibrin unlike human tissue plasminogen activator. Blood 1990; 76: 2560-2564
• 24 Vaughan DE, Declerck PJ, De Mol M, Collen D. Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendancy associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits. J Clin Invest 1989; 84: 586-591
• 25 Montoney M, Gardell SJ, Marder VJ. Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model. Circulation 1995; 91: 1540-1544
• 26 Mellott MJ, Ramjit DR, Stabilito II, Hare TR, Senderak ET, Lynch JJ, Gardell SJ. Vampire bat salivary plasminogen activator evokes minimal bleeding relative to tissue-type plasminogen activators as assessed by a rabbit cuticle bleeding time model. Thromb Haemost 1995; 73: 478-483
• 27 Benedict CR, Refino CJ, Keyt BA, Pakala R, Paoni NF, Thomas GR, Bennett WF. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 1995; 92: 3032-3040
• 28 Schick LA, Castellino FJ. Interaction of streptokinase and rabbit plasminogen. Biochemistry 1973; 12: 4315-4321
• 29 Johnstone MT, Andrews T, Ware JA, Rudd MA, George D, Weinstein M, Loscalzo J. Bleeding time prolongation with streptokinase and its reduction with l-desamino-8-D-arginine vasopressin. Circulation 1990; 82: 2142-51
• 30 Topol EJ, Bell WR, Weisfeldt ML. Coronary thrombolysis with recombinant tissue-type plasminogen activator. Annal Int Med 1985; 103: 837-843
• 31 Kasper W, Erbel R, Meinertz T, Drexler M, Ruckel A, Pop T, Prellwitz W, Meyer J. Intracoronary thrombolysis with an acetylated streptokinase-plas-minogen activator (BRL 26921) in patients with acute myocardial infarction. J Am Coll Cardiol 1984; 4: 357-363
• 32 Lyden PD, Madden KP, Clark WM, Sasse KC, Zivin JA. Incidence of cerebral hemorrhage after antifibrinolytic treatment for embolic stroke in rabbits. Stroke 1990; 21: 1589-1593
• 33 Clark WM, Madden KP, Lyden PD, Zivin JA. Cerebral hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits. Stroke 1991; 22: 872-876
• 34 Okada Y, Yamaguchi T, Minematsu K, Miyashita T, Sawada T, Sadoshima S, Fujishima M, Omae T. Hemorrhagic transformation in cerebral embolism. Stroke 1989; 20: 598-603
• 35 Niewiarowski S, Senyi AF, Gillies P. Plasmin-induced platelet aggregation and platelet release reaction. Effects on hemostasis. J Clin Invest 1973; 52: 1647-1659
• 36 Rudd MA, George D, Amarante P, Vaughan DE, Loscalzo J. Temporal effects of thrombolytic agents on platelet function in vivo and their modulation by prostaglandins. Circ Res 1990; 67: 1175-1181
• 37 Penny WF, Ware JA. Platelet activation and subsequent inhibition by plas-min and recombinant tissue-type plasminogen activator. Blood 1992; 79: 91-98